Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-03-04 22:43 |
Cellectis publie ses résultats financiers du quatrième trimestre 2020 et de l’e…
|
French | 386.1 KB | ||
| 2021-03-04 22:42 |
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 F…
|
English | 390.0 KB | ||
| 2021-02-25 22:30 |
Cellectis to Hold Fourth Quarter 2020 Earnings Call on Friday, March 5, 2021 at…
|
English | 68.5 KB | ||
| 2021-02-25 22:30 |
Cellectis organise une conférence téléphonique pour présenter ses résultats fin…
|
French | 68.3 KB | ||
| 2021-02-16 07:00 |
Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-D…
|
English | 123.7 KB | ||
| 2021-02-16 07:00 |
Cytovia Therapeutics et Cellectis s’associent pour développer des cellules NK d…
|
French | 129.3 KB | ||
| 2021-02-10 22:30 |
Cellectis : Information mensuelle relative au nombre total des droits de vote e…
|
French | 76.8 KB | ||
| 2021-02-10 22:30 |
Cellectis: Monthly information on share capital and company voting rights
|
English | 75.2 KB | ||
| 2021-01-06 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 72.8 KB | ||
| 2021-01-06 22:30 |
Monthly information on share capital and company voting rights
|
English | 71.2 KB | ||
| 2020-12-16 02:16 |
Cellectis annonce le retrait de son offre d’ADS
|
French | 140.7 KB | ||
| 2020-12-16 02:15 |
Cellectis Announces Withdrawal of Follow-On Offering
|
English | 120.9 KB | ||
| 2020-12-14 22:19 |
Cellectis annonce le lancement d’une nouvelle offre d’ADS
|
French | 139.3 KB | ||
| 2020-12-14 22:18 |
Cellectis Announces Launch of Follow-On Offering
|
English | 156.3 KB | ||
| 2020-12-08 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 75.8 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
